MerTK Inhibitors Market, By Role of process (Macrophage clearance of apoptotic cells, Platelet aggregation, Cytoskeleton reorganization, Engulfment and Others), By Phase (Phase I, Phase II and Others), By End-user, (Specialty Clinics, Research & Laboratories and Others), and By Region - Market Trends, Analysis, and Forecast till 2030

Market for MerTK Inhibitors was valued at US$ 280.719 million in 2020 and is projected to grow at a compound annual growth rate (CAGR) of 7.1% to reach US$ 558.8 million by 2030.

It has been discovered that several cancers, including leukemia, melanoma, and gastric cancer (GC), express MerTK (MER tyrosine kinase). A critical component of the oncogenesis pathway is MerTK. More than 80% of acute myeloid leukemia (AML) and 30 to 50% of acute lymphoblastic leukemia (ALL) ectopically express MerTK, a possible therapeutic target. Mer is a member of the TAM (TYRO3-AXL-MER) family of receptor tyrosine kinases, which, when activated, control the survival, proliferation, migration, invasion, and interactions between tumor cells and their hosts. The MerTK pathway also initiates innate immune activation. There is mounting evidence that these receptors are essential in the development of resistance to both conventional cytotoxic drugs and targeted medications. In dendritic cells, macrophages and MerTK have been recognized as an immunological checkpoint in relation to other immune cells.